Circassia Pharmaceuticals Plc Notification of Major Interest in Shares (3813C)
13 April 2017 - 2:34AM
UK Regulatory
TIDMCIR TIDMAZN
RNS Number : 3813C
Circassia Pharmaceuticals Plc
12 April 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------------------------------------------------------
1. Identity of the issuer or Circassia Pharmaceuticals
the underlying issuer plc
of existing shares to which
voting rights are
attached: (ii)
--------------------------------------------------------------- ---------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
--------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights X
------------------------------------------------------------------ ------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
------------------------------------------------------------------ ------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
------------------------------------------------------------------ ------------------------------
An event changing the breakdown of voting rights
------------------------------------------------------------------ ------------------------------
Other (please
specify):
--------------------------------------------------------- ------- ------------------------------
3. Full name of person(s) AstraZeneca PLC
subject to the
notification obligation:
(iii)
----------------------------------------------------------- -------------------------------------
4. Full name of shareholder(s) AstraZeneca UK Limited
(if different from 3.):(iv)
----------------------------------------------------------- -------------------------------------
5. Date of the transaction 12 April 2017
and date on
which the threshold is
crossed or
reached: (v)
----------------------------------------------------------- -------------------------------------
6. Date on which issuer 12 April 2017
notified:
----------------------------------------------------------- -------------------------------------
7. Threshold(s) that is/are 3% through to 14% (inclusive)
crossed or
reached: (vi, vii)
----------------------------------------------------------- -------------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- ----------------------------------- ------------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights (x)
Shares Voting
Rights
------------- ---------------- ----------------- -------------- ----------------------- -------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ------------ ------------- -------------- --------- ------------ ------------ -----------
Ordinary
shares of
0.08 pence 0 0 47,355,417 0 47,355,417 0 14.25%
---------------- ----------------- -------------- --------- ------------ ------------ -----------
GB00BJVD3B28
------------- ------------ ------------- ------------ ------- ------------ -------- ---------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument (xiii) Period (xiv) may be
acquired if
the
instrument
is
exercised/
converted.
----------------- -------------- --------------------------------- ------------------------- ---------------------
N/A
----------------- -------------- --------------------------------- ------------------------- ---------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date Conversion rights instrument rights (xix,
instrument (xvii) period refers to xx)
(xviii)
--------------- -------------- --------------- ---------------- ------------------------- -----------------------
N/A Nominal Delta
--------------- -------------- --------------- ---------------- ------------------------- ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
---------------------------------------------------- ----------------------------------------------------------------
47,355,417 14.25%
---------------------------------------------------- ----------------------------------------------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
(xxi)
-------------------------------------------------------------------------
AstraZeneca PLC (parent Company)
AstraZeneca Intermediate Holdings Limited (wholly owned
subsidiary of AstraZeneca PLC)
AstraZeneca UK Limited (99.994% owned by AstraZeneca
Intermediate Holdings Limited and 0.006% owned by AstraZeneca
PLC) - holder of 47,355,417 Ordinary Shares in Circassia
Pharmaceuticals plc
Proxy Voting:
-------------------------------------------------------------------------
10. Name of the proxy holder: N/A
---------------------------------------------------------- -------------
11. Number of voting rights proxy N/A
holder will cease
to hold:
---------------------------------------------------------- -------------
12. Date on which proxy holder will N/A
cease to hold
voting rights:
---------------------------------------------------------- -------------
13. Additional information:
---------------------------------------------------------- -------------
14. Contact name: Julien Cotta
---------------------------------------------------------- -------------
15. Contact telephone number: 01865 405560
---------------------------------------------------------- -------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLITMFTMBTBBLR
(END) Dow Jones Newswires
April 12, 2017 12:34 ET (16:34 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024